Last mentioned: Mar 9, 2026
Pipeline Expansion
Expected utilization of funds to advance additional candidates from the OPERA platform.
Clinical Milestone Expected
Anticipated progress updates on the KRRO-110 Phase 1/2 clinical trial for AATD.
Private Placement Announced
Korro Bio announces the closing of an $85 million oversubscribed private placement.
Korro Bio has announced an oversubscribed $85 million private placement to accelerate its proprietary RNA editing platform and clinical development. The funding provides a significant runway for the company's lead program, KRRO-110, targeting Alpha-1 Antitrypsin Deficiency.
Korro Bio (NASDAQ: KRRO) has successfully closed an $85 million private placement, signaling strong investor confidence in its proprietary RNA editing platform. The capital infusion is earmarked for the clinical advancement of its lead candidate, KRRO-110, and the expansion of its OPERA platform.